Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

H3K27me3 conditions chemotolerance in triple-negative breast cancer
Justine Marsolier, Pacôme Prompsy, Adeline Durand, et al.
Nature Genetics (2022) Vol. 54, Iss. 4, pp. 459-468
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Single cell cancer epigenetics
Marta Casado-Peláez, Alberto Bueno-Costa, Manel Esteller
Trends in cancer (2022) Vol. 8, Iss. 10, pp. 820-838
Open Access | Times Cited: 77
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Yi Pu, Lu Li, Haoning Peng, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 799-813
Closed Access | Times Cited: 62
Cellular adaptation to cancer therapy along a resistance continuum
Gustavo S. França, Maayan Baron, Benjamin R. King, et al.
Nature (2024) Vol. 631, Iss. 8022, pp. 876-883
Closed Access | Times Cited: 38
Pharmacological targeting of the cancer epigenome
Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 844-865
Closed Access | Times Cited: 20
PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells
Yun Li, Hengxing Chen, Xuan Xie, et al.
Cancer Research (2022) Vol. 83, Iss. 3, pp. 398-413
Open Access | Times Cited: 57
Redox signaling in drug-tolerant persister cells as an emerging therapeutic target
Zhe Zhang, Yunhan Tan, Canhua Huang, et al.
EBioMedicine (2023) Vol. 89, pp. 104483-104483
Open Access | Times Cited: 36
Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment
Linlin Zhou, Danny Yu
Pharmacological Research (2024) Vol. 204, pp. 107205-107205
Open Access | Times Cited: 16
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Mariangela Russo, Mengnuo Chen, Elisa Mariella, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 10, pp. 694-717
Closed Access | Times Cited: 15
Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going?
Anthony Sloan, Daniel J. Silver, Sam Kint, et al.
Neuro-Oncology (2024) Vol. 26, Iss. 5, pp. 785-795
Closed Access | Times Cited: 12
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse
Mengnuo Chen, Sara Mainardi, Cor Lieftink, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101471-101471
Open Access | Times Cited: 12
Epigenomic heterogeneity as a source of tumour evolution
Marthe Laisné, Mathieu Lupien, Céline Vallot
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 9
Patient-Derived Xenografts of Breast Cancer
Elisabetta Marangoni
Advances in experimental medicine and biology (2025), pp. 109-121
Closed Access | Times Cited: 1
Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness
Rinad Mahmoud, Paloma Ordóñez‐Morán, Cinzia Allegrucci
Cancers (2022) Vol. 14, Iss. 17, pp. 4280-4280
Open Access | Times Cited: 34
GSK‐J4: An H3K27 histone demethylase inhibitor, as a potential anti‐cancer agent
Nidhi Dalpatraj, Ankit Naik, Noopur Thakur
International Journal of Cancer (2023) Vol. 153, Iss. 6, pp. 1130-1138
Closed Access | Times Cited: 22
Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated
Keywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Medical Oncology (2022) Vol. 39, Iss. 12
Closed Access | Times Cited: 28
Doxorubicin loaded hydrogel microparticles from microfluidics for local injection therapy of tumors
Xiao Ma, Caihong Yang, Ruirui Zhang, et al.
Colloids and Surfaces B Biointerfaces (2022) Vol. 220, pp. 112894-112894
Closed Access | Times Cited: 26
Phenotypic noise and plasticity in cancer evolution
Frederick J.H. Whiting, Jacob Househam, Ann‐Marie Baker, et al.
Trends in Cell Biology (2023) Vol. 34, Iss. 6, pp. 451-464
Open Access | Times Cited: 15
Tellurium-driven maple leaf-shaped manganese nanotherapeutics reshape tumor microenvironment via chemical transition in situ to achieve highly efficient radioimmunotherapy of triple negative breast cancer
Wei Huang, Sujiang Shi, Haoran Lv, et al.
Bioactive Materials (2023) Vol. 27, pp. 560-573
Open Access | Times Cited: 14
Hybrid Cell Membrane‐Coated Nanoparticles for Synergizing Sonodynamic Therapy and Immunotherapy against Triple‐Negative Breast Cancer
Jiali Gong, Danling Cheng, Changcun Liu, et al.
Advanced Healthcare Materials (2024)
Open Access | Times Cited: 6
A low-input high resolution sequential chromatin immunoprecipitation method captures genome-wide dynamics of bivalent chromatin
Janith A. Seneviratne, William Wing Ho Ho, Eleanor Glancy, et al.
Epigenetics & Chromatin (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Research progress and applications of epigenetic biomarkers in cancer
Jianjun Gao, Wujiang Shi, Jiangang Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer
Majid Momeny, Mari Tienhaara, Mukund Sharma, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 7, pp. 1603-1629
Open Access | Times Cited: 5
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation
Tao Zhang, Zilu Pan, Jing Gao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer
Paras Famta, Saurabh Shah, Naitik Jain, et al.
Life Sciences (2022) Vol. 310, pp. 121125-121125
Closed Access | Times Cited: 22
Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
Xiao-Hai Song, Lan Yang, Xiuli Zheng, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top